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Introduction: Most conventional drug delivery systems are not acceptable for
pediatric patients as they differ in their developmental status and dosing
requirements from other subsets of the population. Technology platforms
are required to aid the development of age-appropriate medicines to
maximize patient acceptability while maintaining safety, efficacy, accessibility
and affordability.
Areas covered: The current approaches and novel developments in the field
of age-appropriate drug delivery for pediatric patients are critically discussed
including patient-centric formulations, administration devices and packaging
systems.
Expert opinion: Despite the incentives provided by recent regulatory modifi-
cations and the efforts of formulation scientists, there is still a need for imple-
mentation of pharmaceutical technologies that enable the manufacture of
licensed age-appropriate formulations. Harmonization of endeavors from
regulators, industry and academia by sharing learning associated with data
obtained from pediatric investigation plans, product development pathways
and scientific projects would be the way forward to speed up bench-to-
market age appropriate formulation development. A collaborative approach
will benefit not only pediatrics, but other patient populations such as geriat-
rics would also benefit from an accelerated patient-centric approach to drug
delivery.
Keywords: acceptability, age-appropriate, formulation development, oral drug delivery system,
pediatric drug delivery, technology platform
1. Introduction
Pediatric patients require different oral drug delivery systems than other subsets of
the population due to their continuing development hence dosing and administra-
tion requirements [1]. Conventional formulations are not designed for this patient
group; thus, manipulation and compounding has become common practice [2].
Age-appropriate oral drug delivery systems specifically developed to meet the needs
of the pediatric population are therefore desired. In terms of adherence and concor-
dance geriatric patients would also benefit from patient-centric formulation design
tailored to overcome the impaired physiological, visual, motoric functions and
swallowing capabilities.
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The development of an age-appropriate formulation is a
challenging task due to the broad range of pharmaceutical
and clinical aspects that must be considered in order to ensure
the quality, safety and efficacy of the final product. In partic-
ular, the development of pediatric formulations is complex
due to the additional needs and demands of this target popu-
lation with respect to adults. The pharmacokinetic and phar-
macodynamic profile of a drug varies broadly depending on
the developmental stage of a child, necessitating dose flexibil-
ity to suit the dosing requirements across all age groups [3].
Excipients commonly regarded as safe may represent a safety
risk for children adding other considerations into the formu-
lation development [4]. Palatability and ease of swallowing
are also considered as critical attribute for the acceptability
of medicines intended for children, who possess distinct
preferences and swallowing abilities than other subsets of the
population. In many cases, the dependence on caregivers
also influences the administration and acceptability of
medicines [5].
In addition to all the factors mentioned above there are
manufacturing, processing and packaging aspects to bring
into the equation. The manufacturing process of pharmaceu-
tical products must be robust and able to deliver medicines of
adequate quality at an affordable price. Packaging and admin-
istration devices must be seen as an integral part of the prod-
uct as these can improve the overall quality and acceptability
of the medication [6,7], while minimizing its cost. The afford-
ability of medicines is crucial for the development of pharma-
ceutical products for global market, including developing
countries [8]. The utilization of cost-effective and readily-
available technologies is often desired to maximize the
affordability and accessibility of medicines, which ultimately
benefits healthcare providers and patients. Therefore balance
between innovative technologies and patient access to
medicines must be sought.
An ideal formulation must gather a number of require-
ments to meet with the needs of patients, caregivers, manufac-
turers and healthcare providers. The numerous criteria that
must be considered along the development of
age-appropriate products has been classified into three main
categories: i) factors related to efficacy and ease of use;
ii) those related to patient safety; and iii) factors influencing
the access of patients to medicines, as detailed in (Table 1)
[9]. Considering the number of parameters that needs to be
fulfilled, one single formulation development approach is
less likely to be appropriate for all patients. Thus flexible
technology platforms are desired enabling the preparation of
formulations with different active pharmaceutical ingredients
(APIs), dose strengths and/or release profiles [1,10].
In recent years there has been an increased focus on the
development of novel technologies for the preparation of
age-appropriate formulations, supported by modifications in
the regulatory framework [11]. This has resulted in a noticeable
increase in the formulation design approaches (e.g., dispers-
ible tablets, oral films and minitablets) and administration/
dosing devices (e.g., medicated straw and minitablets dispens-
ers) that has been investigated, patented and commercialized.
Examples of technologies that have emerged during the past
two decades are illustrated in (Figure 1). In this article, the
current strategies for the development of oral drug delivery
systems for pediatric patients are reviewed and their benefit
and limitations critically discussed. The main focus of this
work lay on marketed products and technologies as well as
those close to market.
2. Recent advances in conventional oral drug
delivery systems
Conventional solid (tablets and capsules) as well as liquid
(solutions and suspensions) dosage forms exhibit limitations
for the delivery of drugs to pediatric patients. In this section
particular barriers for manufacturability and patient adminis-
tration are discussed and recent developments to overcome
existing limitations are reviewed.
2.1 Liquid dosage forms
Due to the inherent limitations of liquid dosage forms with
respect to solid dosage forms (e.g., stability issues, challenging
controlled release or higher transportation costs) the efforts of
formulation scientists have been directed towards the develop-
ment of solid formulations over liquids. However, liquid
dosage forms may be favorable for certain patients (e.g.,
neonates and infants) due to the increased dose flexibility
and ease of swallowing in comparison to solid products.
Current developments have been focused on the design of
Article highlights.
. Age-appropriate oral formulations are expected to meet
all the quality attributes of conventional pharmaceutical
products as well as specific patient requirements (e.g.,
higher degree of dose flexibility and ease of
swallowing).
. The most popular technologies to date have been for
the manufacture of small-sized solid oral drug delivery
systems (e.g., minitablets and multiparticulates) and
orally dispersible products (e.g., orodispersible tablet,
orodispersible films and chewable formulations).
. Age-appropriate administration devices (e.g., the solid
dosage pen, multiparticulate counters and medicated
straws) may improve the acceptability of pharmaceutical
products.
. Not only pediatric patients but also geriatric patients and
adults with reduced capability to take conventional solid
formulations may benefit from patient-centric
approaches to drug delivery.
. A balanced approach between innovation and
cost-effectiveness is required to enable high-quality
products while not-impairing patient access to better
medicines.
This box summarizes key points contained in the article.
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dry solid formulations to be converted to liquid at the point of
administration.
One of the major limitations of liquid products with regard
to patient acceptability is the lack of controlled release formu-
lations resulting in the need to administer multiple doses
throughout the day. A number of approaches have been inves-
tigated for the development of sustained release liquids, such
as ion exchange resins, coated microparticles in suspension
or drug microemulsions, among others [12-14]. The relative
success of each of these approaches is controversial. Neverthe-
less, few sustained release liquid formulations are available in
the market such as azithromycin extended release (first
extended release suspension) and methylphenidate hydrochlo-
ride extended release oral suspension [15-17].
Recent work has been directed towards the investigation of
appropriate vehicles for pediatric formulations with improved
palatability. For example, milk has been explored as a vehicle
in liquid formulations showing potential for solubilizing
drugs while maintaining the stability of the emulsified vehi-
cle [18,19]. The use of milk as a vehicle for the administration
of drugs was also at the background of the development of a
‘nipple shield’ delivery system (Figure 2), which is designed
to accommodate a drug-loaded insert delivering the API
into milk while breastfeeding neonates [20,21]. Lipid-based
vehicles are promising by providing solubilization of highly
lipophilic drugs as well as masking the unpleasant taste [22].
Besides, self-emulsifying drug delivery systems can potentially
be prepared as solid dosage forms for reconstitution [23].
An interesting growing field related to liquid dosage forms
is the development of administration devices. Several dosing
devices have been designed such as a baby bottle coupled to
a syringe for aiding the administration of liquid formula-
tions [24]. Others include modified pacifiers and the ‘dose sip-
ping syringe,’ which can be used either as a conventional oral
syringe or as a straw for the administration of liquid medi-
cines [25,26]. The main potential limitation for wider applica-
bility of these devices is the overall cost of the product.
2.2 Solid dosage forms
Solid drug delivery systems have been the formulation of
choice for pharmaceutical industry due to the pros of well-
established technology platforms enabling long-term stability,
easing supply chain and maintaining low manufacturing cost.
However, conventional solid forms may not be suitable for
patients with swallowing difficulties, in particular for pediatric
populations. Administration devices such as ‘pill swallowing
cups’ have been used to increase the suitability of tablets and
capsules of relatively large size to a broader population
range [27]. However, acceptability studies are required to dem-
onstrate the applicability of this type of devices in the most
vulnerable populations with maximum need (e.g., infants).
Additionally, education and training has proven to be a useful
approach to facilitate swallowing of solid dosage forms [28].
Another limitation of conventional tablets is their poor
flexibility of dose. Inevitably pill splitting has become usual
daily practice to obtain various dose strengths. The use of ‘pill
splitters’ is widespread despite the safety and efficacy risk of
this practice [29,30]. In order to remove the risk, methodologies
to improve the dose flexibility of single-unit dosage forms
have been explored. Kayitare et al. developed a tablet that
can be accurately scored into eight segments [31], whereas Sol-
omon and Kaplan patented a novel technology for the prepa-
ration of tablets containing drug-free layers to aid accurate
division without compromising the accuracy of the delivered
dose [32]. An interesting development is the solid dosage
pen, which consists of a cylindrical rod manufactured by
mass-extrusion and incorporated into a pen-like device that
allow dosing adjustments by cutting small tablet-like slices
of the required length [33,34].
Smaller tablets and capsules emerge as an alternative to
conventional solid dosage forms with improved dose flexibil-
ity hence ease of swallowing. Several studies have shown that
young children from the age of 6 months are able to swallow
single minitablets [35,36]. Moreover, 2 mm minitablets proved
to be more acceptable than syrups even for the very young
subgroups (6 -- 12 months old) [36]. Nevertheless, the maxi-
mum dose that can be delivered by single-unit minitablets
will always be limited by their small size. In consequence, sev-
eral of these small-sized tablets are typically required in order
to achieve the targeted dose. The administration of multiple
minitablets is further discussed in the following section dedi-
cated to multiparticulate drug delivery systems.
Table 1. List of requirements for age-appropriate oral
drug delivery systems.
Benefit/risk Criterion for
drug product
Product requirements
Efficacy/
acceptability
Dosage Dose flexibility
Acceptability of size/volume
Preparation/
administration
Easy and convenient handling
Easily administered (correct
use)
Compliance Minimal impact on lifestyle
Acceptable appearance and
taste
Minimal administration
frequency
Patient safety Bioavailability Adequate bioavailability
Excipients Minimal number of excipients
Tolerability
Stability Stable during shell life
Stable in-use
Medication error Minimal risk of dosing error
Patient
access
Manufacturability Robust manufacturing process
Commercial viability
Affordability Acceptable cost to patient and
payers
Easily transported and stored
Low environmental impact
Data taken from [9].
Formulation approaches to pediatric oral drug delivery
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New packaging systems of solid dosage forms are also
evolving with the aim of improving both the safety and the
acceptability of medicines. Compliance-prompting packaging
include printed blisters to facilitate self-monitoring of the
treatment (calendar packaging) plus guidelines for correct
administration which, in combination with education and
other reminder strategies when needed, may improve medica-
tion adherence [37].
3. Novel approaches to age-appropriate oral
drug delivery
In this section new formulation design approaches are
reviewed, including multiparticulate drug delivery systems,
orodispersible tablets (ODTs), orodispersible films (ODFs),
and chewable formulations. The parameters listed in Table 1
are used as a guidance to critically discuss the advantages
and limitations of each technology platform.
3.1 Multiparticulate drug delivery systems
Multiparticulate drug delivery systems are composed of a
number of discrete units such as granules, pellets or minitab-
lets. Multiparticulate products are expected to provide
improved patient acceptability over single-unit solid dosage
forms (i.e., tablets and capsules) by dint of their reduced size
and thus improved ease of swallowing plus the increased
dose flexibility provided by their multi-unit composition.
Moreover, multiparticulate products are usually suitable for
controlled release and taste masking by means of film-coating
technologies, which can also benefit patient’s compliance.
Insert containing active agent
Modified silicone
nipple-shield
Lip to hold insert
Figure 2. Schematic illustration of the nipple shield device (left) and image of a prototype device including drug delivery
insert (right).
Reproduced from [20] with permission of Justmilk.org.
Oral dispenser coupled
to baby bottle
Orodispersible tablet
1995 2015Approximate timeline
Commercialised technology
Non-commercialised technology
Pill swallowing cup Sustained releasesuspension Oral soluble film Easy-to-open capsules
Medicated dosing
straw
Segmented easy-to-score
tablet
(Solomon and Kaplan, 2007)
Electronic mini-tablet
dispenser
(Bredenberg et al., 2003)
Gel-forming easy-to-
swallow oral film
(Okabe et al., 2008)
Solid dosage pen device
(Wening and Breitkreutz, 2010)
Nipple shield drug
delivery device
(Gerrard et al., 2013)
Milk-based oral liquid
formulation
(Charkoftaki et al., 2012)
Multiple scored tablet
(Kayitare et al. 2009)
Medicated spoon that
forms oral pulp
Chewable soft-gel
capsules
3D printed
orodispersible tablet
Figure 1. A range of formulations and devices for age-appropriate oral drug delivery, which have emerged during the past
two decades. Green triangles above: commercialized dosage forms and devices; Blue triangles below: non-commercialized
dosage forms and devices. This is not intended to be an exhaustive list but exemplify progress.
F. L. Lopez et al.
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Characteristic advantages and limitations of multiparticulate
drug delivery systems are summarized in Table 2.
Small particulates may be easier to swallow and thus more
acceptable than single-unit formulations for certain popula-
tions. However, the acceptability of multiparticulates in terms
of grittiness or mouthfeel is not fully understood [38,39], possi-
bly limiting the development of these products. There is also a
lack of evidence on the size and amount of multiparticulates
that is acceptable to patients, although recent FDA guidance
suggests a maximum targeted size of 2.5 mm [40]. Research
is required in this area, where the utilization of robust predic-
tive models to assess palatability is desired as it could avoid the
hurdles of conducting clinical trials [41]. Meanwhile, oral gels
and in situ gelling vehicles are being studied as media to aid
the administration of multiparticulate formulations [42]. Mul-
tiparticulates can be directly administered into the patients’
mouth or dispersed in a vehicle prior to administration as pre-
ferred. Water, milk, juice or apple sauce are potential vehicles
commonly proposed [43]. The administration of multiparticu-
lates in admixture with food (‘sprinkling’) is often indicated
to improve the organoleptic properties and thus the accept-
ability of these formulations. However, despite of the
potential to improve palatability, the need for product prepa-
ration may actually have a negative impact on the overall
acceptability of the product as shown in recent studies [44,45].
In addition, the co-administration of drug products with
food or drinks causes safety concerns, such as poor control
over dose intake and impact on drug’s bioavailability [46].
Therefore, the influence of this practice on the product safety
and efficacy should be considered beforehand. In this respect
Albertini et al. investigated the compatibility of solid lipid
microparticles in milk and yogurt as suitable vehicles for pedi-
atric administration [47]. In any case, the need for product
manipulation by the patient or caregiver should always be
kept to a minimum.
The multi-unit composition of multiparticulate drug deliv-
ery systems offers attractive opportunities for the preparation
of fixed-dose combinations and products with targeted
release profiles, which can reduce the burden of repeated
administration [48]. This can be achieved by simply combining
multiparticulates with different APIs and/or different release
characteristics into the same dosage form, respectively. An
advantage of multiparticulates over single-unit formulations
is that controlled release and thus improved bioavailability
can be provided while avoiding the risk of dose-dumping
[49]. In addition, multiparticulate products have been reported
to provide a more reproducible distribution in the gastro-
intestinal tract with lower risk of local irritation, although
knowledge in this field is still limited and subjected to a
high degree of inter- and intra-individual variability [50].
There is a broad range of manufacturing techniques that
can be used to prepare multiparticulate products, with
extrusion-spheronization and active layering the most com-
monly reported. Other manufacturing methods for the prep-
aration of multiparticulates include fluid bed granulation [51],
spray-drying [52], and microencapsulation techniques [53,54].
As for production of adult medicines, single-step manufactur-
ing (direct pelletization) is preferred over multi-step processes
in order to reduce cost and variability [55]. All these technolo-
gies render spherical particulates of small diameter (typically
< 1.5 mm). In addition, minitablets of 1 -- 3 mm can be pre-
pared by conventional tableting equipment, using either small
conventional tooling or specialized accessories [56]. The pro-
duction of mini-tablets is often more demanding than larger
tablets and thus an excellent understanding and control of
processing variables is needed and specialized excipients are
often required in order to obtain the targeted flow and
Table 2. Advantages and disadvantages of multiparticulates for the preparation of age-appropriate products.
Product
characteristic
Advantages Disadvantages
Efficacy/acceptability
Dosage Excellent flexibility of dose
Small size/swallowing is aided
Grittiness/mouthfeel may be an issue
Preparation Flexibility of administration Need for preparation/reconstitution
Compliance Ease of functionalization
Suitable for taste masking
Safety profile
Bioavailability Highly reproducible due to uniform GI transit
Targeted release profiles can be achieved
Co-administration with food/drinks may alter bioavailability
Excipients Use of Generally Regarded As Safe (GRAS) excipients
Stability Food-drug compatibility needs to be studied
Medication error Limited control over dose intake when mixed with food
Patient access
Manufacturability May need specialize equipment or accessories
Affordability Manufacturing technology readily available Need to develop packaging/dosing technology platform
Formulation approaches to pediatric oral drug delivery
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compression properties [57]. The manufacturing process
of multiparticulate products usually include a polymeric
coating step as downstream processing for improved aesthet-
ical properties, taste masking and/or controlled release
functionalization.
Multiparticulates also offer a great degree of flexibility in
terms of presentation and packaging. First, these formulations
can be filled into capsules, although this could limit their
swallowing advantage unless presented as an easy-to-open
capsule to the patient [58]. In addition, multiparticulate prod-
ucts can be prepared as single-dose sachets, which allow for
higher doses than tablets or capsules. Moreover, granules or
pellets can be incorporated into medical devices to aid admin-
istration. This is the case of medicated spoons which contain a
single-dose granulated formulation that can be designed to be
either dispersed in a beverage prior to administration [59] or
submerged in water to form an easy-to-administer pulp [25].
Another example of administration devices is the dose sipping
technology in which a pre-dosed granulated medicine is filled
into a ready-to-use straw (Figure 3) [26]. This technology
reached the market for the oral delivery of the antibiotic clar-
ithromycin but due to commercial pressures the availability of
the product was limited after few years of commercialization.
The aforementioned approaches are intended as single-dose
presentations, besides multi-dose presentations may also be
considered providing further advantages in terms of dose flex-
ibility. This would require the utilization of dosing devices to
allow adjustment of the dose by measuring different amounts/
volumes of multiparticulates from a pre-filled multi-dose
pack. Research has been conducted in this direction and sev-
eral patents have been filled with devices ranging from dosing
spoons to electronic dispensers [7]. In general, volumetric
spoons are the most cost-effective approach, although their
success to achieve accurate dosing is limited (which is particu-
larly important for drugs with a narrow therapeutic index).
More sophisticated devices can lead to highly accurate dosing
by counting, although these technologies may be more costly
to develop and produce. The applicability of these devices to
accommodate different formulations (potentially with a dif-
ferent size and/or shape) is desirable in order to reduce costs.
More detailed information about devices for oral administra-
tion can be found in a recent review by Wening and
Breitkreutz [7].
3.2 Orodispersible tablets
ODTs are designed to disintegrate in the oral cavity within a
matter of seconds, avoiding the need for swallowing the tablet
as a whole [60]. In some cases, when the disintegration/
dissolution is sufficiently fast, the use of water can also be
avoided. Moreover, ODTs offer great flexibility in terms of
administration, as the tablet may be pre-dispersed in a suitable
vehicle, dispersed directly in the mouth or even swallowed as a
whole as preferred. Owing to these benefits, patients’ accept-
ability and compliance can be improved with respect to con-
ventional formulations. The main characteristics of ODT
formulations are summarized in Table 3 and are further dis-
cussed below.
Although ODTs facilitate administration and swallowing,
this formulation design do not bring an advantage in terms
of dose flexibility with respect to conventional tablets,
meaning that various dosing strengths would be required to
fulfill the needs of all populations. In addition, owing to the
fragility of ODT formulations, tablet splitting is usually con-
traindicated [15], which may further reduce dose flexibility.
These limitations could potentially be overcome via prepara-
tion of ‘orally disintegrating minitablets’, an interesting
opportunity to combine the benefits of ODTs and
multiparticulates [61].
ODTs can be swallowed once disintegrate in the mouth to
provide drug absorption mostly along the gastrointestinal
tract or, alternatively, retained in the mouth for sublingual
or buccal absorption, which may offer advantages in terms
of onset of action and bioavailability for those drugs that
can be absorbed through the oral mucosa. Formulations
designed for buccal absorption may incorporate a bio-
adhesive layer to facilitate retention of the formulation in
the oral cavity and/or to target a particular absorption site
inside the mouth [62]. The intended use of ODTs must be
clearly stated to avoid medication errors as the formulations’
retention time in the mouth could potentially alter the bio-
availability of the drug.
As the drug is subject to the patients’ taste buds in the
mouth, taste masking is a requirement of orally disintegrating
formulations with unpleasant tasting APIs. Improved palat-
ability is traditionally achieved by addition of sweeteners
and flavors to the formulation. However, the efficacy of this
approach is often limited and, in addition, the use of these
excipients poses safety concern (especially for pediatric
patients) [63]. Coating of the drug particles represents an effec-
tive way of taste masking, however technologically more chal-
lenging [63,64]. Nevertheless, patented ODT technologies have
Figure 3. Dose sipping technology: prototype straw contain-
ing granulated product with removable cap (left) and
without cap, ready-to-use in a glass of water (right).
F. L. Lopez et al.
Expert Opin. Drug Deliv. (2015) 12(11)1732
D
ow
nl
oa
de
d 
by
 [8
6.2
0.2
51
.89
] a
t 0
6:1
2 0
9 D
ec
em
be
r 2
01
5 
been able to overcome this challenge through the preparation
and subsequent compression of microencapsulated drugs
for improved organoleptic properties and/or polymer-coated
particles for customized release [65].
There are various approaches for the development of
ODTs including lyophilization, direct compression, tablet
molding, flash heat processing and lately 3D printing technol-
ogy. Lyophilization and direct compression are by far the
most commonly used manufacturing methods. In general
terms, lyophilized tablets are mechanically more fragile than
compressed ODTs and often require specialized packaging
to ensure stability. Lyophilized ODTs are also limited by
the maximum dose that can be delivered, usually < 400 mg
for poorly water-soluble drugs and down to ~ 60 mg for
water-soluble drugs [66]. In return, lyophilized ODTs offer
quicker disintegration (often <10 s) than tablets prepared by
compression. Moreover, the formulation development of
compressed ODTs is usually tedious, as it is challenging to
get the right balance between quick disintegration and appro-
priate mechanical strength [66]. The relative benefits and dis-
advantages of the different manufacturing approaches for the
development of ODTs have been widely discussed in the
past; the interested reader is thus referred to previous reviews
of this topic [66-69].
The production of ODTs is highly controlled by patented
technologies. Fast dissolving technology based on a continu-
ous ‘form-fill-freeze’ process in which doses deposited in blis-
ters are lyophilized has been the leading technology in
ODTs [70]. Other ODT technologies have been built on
lyophilization or compression proprietary manufacturing pro-
cesses and branded under different trade names [71]. A very
recent ODT platform is based on 3D printing, which enables
the preparation of ‘sponge-like tablets’ with high drug loading
(up to 1000 mg) and very rapid disintegration (< 10 s), over-
coming some of the limitations of both compressed and
lyophilized ODTs [72].
Despite of the costs derived from the development and
production of ODTs, often subjected to manufacturing
and/or packaging processes that are costly and controlled by
intellectual property rights, the number of ODT products in
the market is rising considerably. Although most of these
products are recommended for adolescents and adults, an
increasing amount of pediatric ODT formulations are also
available for younger children. For example, a recently mar-
keted ODT is recommended for children as young as 1 year
old; the formulation can be directly administered into the
patient’s mouth or, alternatively, dissolved in water for
administration via either an oral syringe or a nasogastric
tube [73].
3.3 Orodispersible films
Drug-loaded ODFs based on polymeric matrices can be
designed to disintegrate quickly in the mouth releasing the
active ingredient. Swallowing is aided by the quick disintegra-
tion/dissolution of ODFs in the oral cavity in a similar
fashion to their predecessor ODTs, eliminating the need of
water for their administration. Moreover, ODFs possess an
elegant appearance and may be preferred by some patients.
An added benefit of films in comparison to tablets is their
increased flexibility of dose, as different strengths can be
achieved by simply cutting films of the required size [74].
A comprehensive list of advantages and disadvantages of
ODFs is provided in Table 4.
An important limitation of ODFs is that taste masking and
controlled release is technologically challenging. The utiliza-
tion of coating techniques for these purposes is limited by
the own nature of the manufacturing process, which usually
involves solubilization of the API [74]. In some cases, sustained
release has been achieved through the preparation of
multi-layered films by combining layers with different
release-controlling polymers. However, the fast-disintegrating
advantage is not purposeful anymore as they are often
Table 3. Advantages and disadvantages of orodispersible tablets for the preparation of age-appropriate products.
Product characteristic Advantages Disadvantages
Efficacy/acceptability
Dosage Various dosage strengths required
Preparation Water is not required
Swallowing is avoided
Flexibility of administration
Lack of mechanical strength
Compliance Preferred over conventional formulations Controlled-release is challenging
Taste masking is challenging
Safety profile
Bioavailability May be improved by buccal absorption
Excipients Excipients of unknown safety profile may be required
Stability Packaging and storage conditions can be critical
Medication error Retention time in mouth may alter bioavailability
Patient access
Manufacturability High doses may not be incorporated
Affordability Technologies subjected to intellectual property rights
Formulation approaches to pediatric oral drug delivery
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designed to adhere onto the buccal mucosa and release the
active ingredient in a timely manner. In addition, the absorp-
tion of drugs through the oral mucosa is limited and thus
controlled release ODFs are often intended for topical
delivery rather than systemic delivery of drugs [75].
ODFs are composed of a polymeric matrix with a drug
embedded, typically manufactured by means of solvent cast-
ing method. By this method, a solution containing the active
ingredient along with the film-forming polymer, plasticizer(s)
and other required excipients is allowed to evaporate leaving a
solid film behind. In some cases metering rollers can be used
to determine the thickness of a wet mass which is subse-
quently dried and cut into pieces of appropriate size to achieve
the desired dose [74]. Alternatively, ODFs can be prepared by
hot-melt-extrusion where the use of solvents is avoided, offer-
ing potential benefits for controlled release and taste mask-
ing [76]. In addition, novel technologies for the preparation
of ODFs are arising, such as electrospinning or ink-jet print-
ing [77,78]. Regardless of the manufacturing method, the
amount of drug that can be loaded in ODFs is very limited
(typically < 60 -- 70 mg [79]) owing the ODFs reduced size
(2 -- 9 cm2) and thickness (25 µm to 2 mm). Although novel
technologies can incorporate higher drug doses of > 100 mg
[80], this amount is still limited and thus only potent drugs
with specific physicochemical properties can be successfully
delivered [72].
ODFs are normally presented to the patient as stamp-like
strips, either in single-dose sachets or contained in multi-
dose packs (Figure 4). Preferably, ODFs should be sealed indi-
vidually in order to improve stability and reduce the risk of
overdosing due to films sticking together [74]. Potentially,
more sophisticated multi-dose dispensers could be used where
the desired dose is achieved by the patient or caregiver by cut-
ting strips of appropriate length from a tape-like supply [81].
However, this approach incurs in higher development and
production costs and may also increase the risk of dosing
errors.
The need for specialize manufacturing and packaging
equipment may reduce the viability of the ODF technologies.
In fact, several commercially available ODF products have
Table 4. Advantages and disadvantages of orodispersible films for the preparation of age-appropriate products.
Product characteristic Advantages Disadvantages
Efficacy/acceptability
Dosage Excellent dose flexibility
Preparation Water is not required
Swallowing is avoided
Compliance May be preferred over conventional formulations Controlled-release is challenging
Taste masking is challenging
Safety profile
Bioavailability May be improved by buccal absorption
Excipients Excipients of unknown safety profile may be required
Stability Specialized packaging often required
Medication error Retention time in mouth may alter bioavailability
Patient access
Manufacturability Continuous manufacturing can be achieved Uniformity of dose may be challenging
Only low doses can be incorporated
Affordability Technologies subjected to intellectual property rights
Solvent-based manufacturing process
Figure 4. Examples of orodispersible films in single-dose (left) and multiple-dose (right) packaging alternatives.
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been discontinued in the past, manufacturing issues and poor
revenue being potential factors behind the market discontinu-
ation of these products [15]. Over-the-counter medicines lead
the market of ODFs, including vitamins and food supple-
ments, breath fresheners, antihistaminics and cough suppres-
sants [79]. The first prescription-only ODF to reach the
market was ondansetron oral-soluble film, indicated for adults
and children from 4 years of age in USA [82].
3.4 Chewable formulations
Chewable formulations (i.e., chewable tablets, soft-chews and
chewing gum) are designed to be mechanically processed in
the mouth to aid disintegration and/or dissolution of the
API. These products offer advantages for their administration
in the sense that swallowing is aided (or avoided in the case of
chewing gum) and water is not required. In addition, chew-
able dosage forms may be preferred by patients over other for-
mulations due to their aesthetic properties. However, as in the
case of ODTs, chewable products do not offer an advantage in
terms of dose flexibility with respect to conventional tablets.
The main advantages and limitations of chewable formula-
tions for the administration of medicines to pediatric patients
are summarized in Table 5.
Disintegration and swallowing of chewable dosage forms is
aided by the patient by means of chewing and/or sucking.
Therefore, taste and mouthfeel become critical attributes
and thus a considerate decision should be made on the selec-
tion of excipients [83]. Sugar-based fillers and sweeteners such
as mannitol, sucrose and sorbitol are often used to improve
palatability. A particular disadvantage of chewable products
is their poor suitability for taste masking and controlled
release by coating techniques, as the formulation is subjected
to a great mechanical stress upon administration. In addition,
the drug release process and thus the therapeutic effect are
dependent on the patient’s chewing ability, which may result
in intra- and inter-individual variability.
The need for chewing of the dosage form may represent a
limitation for the applicability of chewable dosage forms in
the pediatric population. However, available data suggest
that chewable tablets are safe and well-tolerated in children
from 2 years of age [84]. As opposed to chewable tablets the
gum-based core of chewing gums is not meant to be swal-
lowed. For this reason, the time required to achieve complete
dissolution of the API should be determined and stated in the
product label. There is a lack of evidence about the safety of
chewing gum in young children and current guidelines only
recommend its use for children of 6 years or older [85].
Besides, concerns have been raised about the possible misused
of these products which may be appreciated by children as
confectionery [85].
Chewable tablets are typically prepared by compression in a
similar fashion to compressed ODTs, but disintegrating
agents are not included in the formulation. There are also pat-
ented technologies for the preparation of chewable formula-
tions. For example, Paulsen et al. described a manufacturing
method based on tablet molding where the use of water and
elevated temperatures is avoided [86]. Other approaches are
based on soft gelatine capsule technology modified by the
addition of chewable filler, providing the benefits of soft-
gels while avoiding the need for swallowing the capsule as a
whole [87,88]. Pharmaceutical chewing gum is prepared by
addition of artificial resins, waxes and elastomers to the
Table 5. Advantages and disadvantages of chewable tablets for the preparation of age-appropriate products.
Product characteristic Advantages Disadvantages
Efficacy/acceptability
Dosage Various dosage strengths required
Preparation Water is not required
Swallowing is avoided
Compliance May be preferred over conventional formulations Controlled-release is challenging
Taste masking is challenging
Safety profile
Bioavailability May be improved by quick disintegration and
dissolution
May be improved by buccal absorption
Bioavailability may be altered depending on
chewing ability
Excipients Excipients of unknown safety profile may be
required
Stability Soft-chews may be problematic due to water
content
Medication error Retention time in mouth may alter bioavailability
Possible overdose if misused as confectionary
Patient access
Manufacturability May need specialize equipment or accessories
Affordability Manufacturing and packaging technology readily
available
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formulation prior to compression or extrusion [89]. Gum-
based tableting technology has been successfully applied for
the local delivery of drugs such as fluoride and
chlorhexidine [90].
4. Conclusion
The development of age-appropriate pharmaceutical products
is challenging due to the combined demands of industry,
healthcare providers, caregivers and patients. During the past
two decades an important number of age-appropriate products
have been investigated, developed and patented, and some have
gained marketing authorization. The current strategies for the
preparation of age-appropriate oral drug delivery systems
have been reviewed throughout this manuscript.
Unfortunately, the limited information available regarding
acceptability and patient preference of emerging dosage forms
(i.e., ODTs, ODFs, chewable formulations, multiparticulates
and minitablets) for the different age subgroups hinder the
rational selection of one formulation approach over another.
Owing the diversity of the pediatric population and the dis-
cussed limitations of the current technologies it seems
unlikely that a single formulation approach will be acceptable
for all pediatric patients. The selection of a suitable formula-
tion approach for a targeted population group needs to be
carefully considered for each individual product. Further
investigation in this field is desired to allow correlation
between formulation technological aspects and patient accept-
ability that guides such a selection process.
5. Expert opinion
In recent years there has been an important sum of efforts from
regulators, industry and academia towards the development of
patient-centric pharmaceutical products. This has resulted in a
noticeable increase in the number of age-appropriate formula-
tions available for some pediatric indications.
Some of the reviewed formulation approaches for the prep-
aration of age-appropriate drug delivery systems are proving
relative success. In particular, the ODT technology platform
has been commonly visited by industry enable product line
extension as well as addressing pediatric patient needs.
ODFs are also becoming increasingly popular, although there
are technical barriers that need to be overcome to broaden the
spectrum of APIs and doses that can be delivered by ODFs.
Meanwhile, pellets and minitablets offer potential alternatives
for pediatric patients although there is still, even if encourag-
ing, limited evidence to support their suitability for young
children. Paradoxically, most of the multiparticulate products
available in the market are filled/compressed into capsules/
tablets restricting the benefits of multiparticulates for children
such as ease of swallowing and dose flexibility. Besides, the
investigation into devices for individualized dosing of multi-
particulates has not reached out patients yet.
The regulatory incentives for the development of age-
appropriate medicines have been a step forward in terms of
increasing the number of authorized pediatric formula-
tions [91]. Despite this promising increase, manipulation and
compounding still continue to be common practice among
caregivers. Therefore further strategies need to be developed
to guide the research in the field prioritizing not only the
design but also the feasibility and scalability of the
manufacturing process to enable rapid translation of discover-
ies and patented technologies into marketed products in a
cost-effective way. Collaboration between regulators, industry
and academia should continue to evolve to facilitate the pro-
cess ‘from bench to market’.
The selection of the most appropriate formulation design
and excipients needs to be guided by a compendium of patient
safety, manufacturability and end-user requirements (e.g.,
palatability and ease of use). Attempts have beenmade to define
the most appropriate formulation for each particular patient
subgroup [9,85]. However, there is still limited evidence-based
data and thus lack of understanding of the effect of pharmaceu-
tical technologic aspect on patient-related outcomes [92].
Patient acceptability should be considered at an early stage in
the product development pathway rather than as a consequence
of the formulation development process. The development of
robust in vitro analytical tools to predict patient-related out-
comes would be highly desirable to achieve this goal.
Flexible technology platforms are attractive for industry by
enabling the delivery of multiple drugs, dose strengths and
release profiles as well as being acceptable for broader patient
populations. There are cases where age-appropriate formula-
tions are not only favorable for children but also for other spe-
cial patient groups including elderly and adults with reduced
capability to swallow conventional solid formulations [93].
For example, multiparticulate and orodispersible formulations
initially designed for pediatrics may be appropriate for others.
Targeting a larger patient population may improve the com-
mercial viability of pediatric products but caution must be
taken to ensure that this practice does not undermine the
requirements of each patient group. Further research is
required to generate evidence-based data that support the utili-
zation of a particular formulation in different age groups with/
without an additional administration device.
Along with the implementation of technology platforms that
enable the preparation of age-appropriate oral dosage forms,
there are extemporaneous dispensing activities to achieve dose
flexibility for the individual patient. For example, in Japan it
is already common practice among pharmacies to prepare per-
sonalized medicines at the point of administration using
small-scale packaging equipment to fill in sachets with the
required dose of a granulated drug product [94]. Similar interim
practices might be considered globally as long as the quality,
efficacy and safety of the formulation are maintained.
A balanced approach between innovation and cost-effectiveness
must be sought to provide patient acceptability without impair-
ing the access to patients of new medicinal products.
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